MF:EURONEXT PARISWendel SE Analysis

Manulife (MF) is trading just above its 200‑day SMA (33.41 vs 33.30) while the 20‑day SMA sits below the 50‑day SMA, signaling a short‑term pull‑back amid a neutral longer‑term trend. The RSI of 32.8 points to oversold conditions, yet the MACD remains bearish with a negative histogram, and volume has been trending down, limiting immediate upside to the nearby resistance at 37.29. Valuation metrics reinforce a modest case: the trailing P/E of 14.8 is below the industry average of 16.4, the forward P/E drops to 9.3, and the dividend yield stands at a healthy 3.9% with a 57% payout ratio.
The fundamentals show a solid balance sheet—$32.1 bn in cash versus $25.4 bn of debt—and robust free cash flow of $20.8 bn, supporting dividend sustainability. Analysts flag the stock as a “buy” with a target around $34.26, and recent commentary from The Motley Fool highlights Manulife’s diversified insurance and wealth exposure while cautioning on U.S. dollar results, underscoring the importance of geographic and currency considerations for investors.